Moderna (MRNA) Equity Average (2017 - 2025)
Historic Equity Average for Moderna (MRNA) over the last 9 years, with Q3 2025 value amounting to $9.4 billion.
- Moderna's Equity Average fell 2077.08% to $9.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $9.4 billion, marking a year-over-year decrease of 2077.08%. This contributed to the annual value of $12.4 billion for FY2024, which is 2493.25% down from last year.
- Per Moderna's latest filing, its Equity Average stood at $9.4 billion for Q3 2025, which was down 2077.08% from $9.7 billion recorded in Q2 2025.
- In the past 5 years, Moderna's Equity Average registered a high of $19.0 billion during Q1 2023, and its lowest value of $3.2 billion during Q1 2021.
- In the last 5 years, Moderna's Equity Average had a median value of $12.3 billion in 2024 and averaged $12.8 billion.
- Its Equity Average has fluctuated over the past 5 years, first soared by 38788.87% in 2022, then crashed by 3150.62% in 2024.
- Over the past 5 years, Moderna's Equity Average (Quarter) stood at $12.1 billion in 2021, then soared by 52.93% to $18.6 billion in 2022, then dropped by 26.42% to $13.7 billion in 2023, then dropped by 16.41% to $11.4 billion in 2024, then decreased by 17.96% to $9.4 billion in 2025.
- Its Equity Average was $9.4 billion in Q3 2025, compared to $9.7 billion in Q2 2025 and $10.5 billion in Q1 2025.